Bavarian Nordic CEO sees massive sales potential for Covid-19 vaccine after securing state aid

If the company manages to produce a Covid-19 vaccine, the sales potential will be huge, says CEO Paul Chaplin, who is happy about the recent aid agreement reached with the Danish government.

Bavarian Nordic CEO Paul Chaplin | Photo: PR/ Bavarian Nordic

Bavarian Nordic CEO Paul Chaplin predicts huge growth potential for its Covid-19 vaccine, as a EUR 108m financial support agreement with the Danish government fell into place on Monday.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Extra data boosts Lundbeck's agitation case

Pharmaceutical firm Lundbeck has presented positive new data at a US conference as it seeks approval for its candidate Rexulti as a treatment for agitation in Alzheimer’s patients.

Further reading

Related articles

Latest news

See all jobs